Efficacy and safety of autoinjected exenatide once‐weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION‐NEO ‐2 randomized clinical study
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Aims: Glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors treat type 2 diabetes through incretin‐signaling pathways. This study compared the efficacy and safety of the glucagon‐like peptide‐1 receptor agonist exenatide once‐weekly ( M iglyol) suspension for autoinjection ( QWS‐AI ) with the dipeptidyl peptidase‐4 inhibitor sitagliptin or placebo. Materials and methods: In this open‐label, multicentre study of patients with type 2 diabetes who had suboptimal glycaemic control on metformin monotherapy, 365 patients were randomized to receive exenatide 2.0 mg QWS‐AI , sitagliptin 100 mg once daily or oral placebo (3:2:1 ratio). The primary endpoint was change in glycated hemoglobin ( HbA1c ) from baseline to 28 weeks. Results: At 28 weeks, exenatide QWS‐AI significantly reduced HbA1c from baseline compared to sitagliptin (−1.13% vs −0.75% [baseline values, 8.42% and 8.50%, respectively]; P = .02) and placebo (−0.40% [baseline value, 8.50%]; P = .001). More exenatide QWS‐AI ‐treated patients achieved HbA1c <7.0% than did sitagliptin‐ or placebo‐treated patients (43.1% vs 32.0% and 24.6%; both P < .05). Exenatide QWS‐AI and sitagliptin reduced fasting plasma glucose from baseline to 28 weeks (−21.3 and −11.3 mg/dL) vs placebo (+9.6 mg/dL), with no significant difference between the 2 active treatments. Body weight decreased with both active treatments (−1.12 and −1.19 kg), but not with placebo (+0.15 kg). No improvement in blood pressure was observed in any group. The most common adverse events with exenatide QWS‐AI were gastrointestinal events and injection‐site reactions. Conclusions: This study demonstrated that exenatide QWS‐AI reduced HbA1c more than sitagliptin or placebo and was well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 1×
“Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4is) are 2 classes of incretin-based glucoselowering medications recommended for patients with type 2 diabetes (T2D).(1) Both GLP-1RAs and DPP-4is act through the glucagon-like peptide-1 (GLP-1) receptor; GLP-1RAs directly…”
BackgroundDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 1×
“1 kg with exenatide QWS-AI in this study.(9,10,19,20) Similarly, the absence of blood pressure reduction observed in this study, which differs from previous studies of exenatide QW,(9,10,19) may be associated with the lesser body weight loss observed with exenatide QWS-AI.”
ResultDiamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434 · cited 1×
“1 kg with exenatide QWS-AI in this study.(9,10,19,20) Similarly, the absence of blood pressure reduction observed in this study, which differs from previous studies of exenatide QW,(9,10,19) may be associated with the lesser body weight loss observed with exenatide QWS-AI.”
ResultDeFronzo, R. A., Okerson, T., Viswanathan, P., Guan, X., Holcombe, J. H., & MacConell, L. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802418851 · Cited by 373
Nauck, M., Weinstock, R. S., Umpierrez, G. E., Guerci, B., Skrivanek, Z., & Milicevic, Z. (2014) · Diabetes Care · doi:10.2337/dc13-2761 · Cited by 284 · cited 7×
“%) of patients reporting an adverse event. aAdjudicated AEs. saxagliptin or vildagliptin.14 In 7 of the 9 earlier studies, proportions of patients achieving HbA1c levels <7.0% were greater with GLP1RAs than DPP-4is.9,10,12,13,15,16,18 FPG reductions in this trial were less robust than those with exenatide in previous…”
ResultInfluential
Cited by
Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280
Chen, J.-J., Wu, C.-Y., Jenq, C.-C., Lee, T.-H., Tsai, C.-Y., Tu, H.-T., Huang, Y.-T., Yen, C.-L., Yen, T.-H., Chen, Y.-C., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.1169 · Cited by 82
Xie, Z., Hu, J., Gu, H., Li, M., & Chen, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1244432 · Cited by 47
Kang, Y. M., Punov, V., Lim, S., & Nauck, M. A. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16398 · Cited by 20
Kolli, R. T., Aoutla, S., Jyothi, N., Mohamed Kalifa, M. R. H., Raju, A., & Cheenikkal Muralidharan, K. (2025) · Cureus · doi:10.7759/cureus.94926 · Cited by 7
Metadata
- Authors
- Gadde, K. M., Vetter, M. L., Iqbal, N., Hardy, E., Öhman, P., & on behalf of the DURATION‐NEO‐2 study investigators
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2017-03-17
- Volume
- 19
- Issue
- 7
- Pages
- 979-988
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2588441560
- Cited by
- 57
- References
- 5
- FWCI
- 4.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of autoinjected exenatide once‐weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION‐NEO ‐2 randomized clinical study. https://app.cochat.ai/papers/10.1111/dom.12908
- The paper
- Gadde, K. M., Vetter, M. L., Iqbal, N., Hardy, E., Öhman, P., & on behalf of the DURATION‐NEO‐2 study investigators. (2017). Efficacy and safety of autoinjected exenatide once‐weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION‐NEO ‐2 randomized clinical study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12908
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.